LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Sirolimus | 1.11 | uM | LJP6 | 3 | L15 | 72 | hr | 1476 | 2531 | 3694 | 0.6852 | 0.4755 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 1476 | 3438 | 3694 | 0.9307 | 0.8845 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 1476 | 3743 | 3694 | 1.0133 | 1.0221 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 1476 | 3645 | 3694 | 0.9867 | 0.9779 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 1 | J09 | 72 | hr | 1476 | 3788 | 3694 | 1.0254 | 1.0424 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 2 | J09 | 72 | hr | 1476 | 3824 | 3694 | 1.0352 | 1.0586 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 3 | J09 | 72 | hr | 1476 | 4091 | 3694 | 1.1075 | 1.1790 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 1 | L03 | 72 | hr | 1476 | 2747 | 3694 | 0.7436 | 0.5729 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 2 | L03 | 72 | hr | 1476 | 3324 | 3694 | 0.8998 | 0.8331 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 3 | L03 | 72 | hr | 1476 | 3056 | 3694 | 0.8273 | 0.7122 |
| SK-BR-3 | TGX221 | 1.11 | uM | LJP5 | 1 | H21 | 72 | hr | 1476 | 3452 | 3694 | 0.9345 | 0.8908 |
| SK-BR-3 | TGX221 | 1.11 | uM | LJP5 | 2 | H21 | 72 | hr | 1476 | 3624 | 3694 | 0.9810 | 0.9684 |
| SK-BR-3 | TGX221 | 1.11 | uM | LJP5 | 3 | H21 | 72 | hr | 1476 | 3676 | 3694 | 0.9951 | 0.9919 |
| SK-BR-3 | Torin1 | 1.11 | uM | LJP6 | 1 | O15 | 72 | hr | 1476 | 1383 | 3694 | 0.3744 | -0.0423 |
| SK-BR-3 | Torin1 | 1.11 | uM | LJP6 | 2 | O15 | 72 | hr | 1476 | 1337 | 3694 | 0.3619 | -0.0630 |
| SK-BR-3 | Torin1 | 1.11 | uM | LJP6 | 3 | O15 | 72 | hr | 1476 | 1286 | 3694 | 0.3481 | -0.0860 |
| SK-BR-3 | Torin2 | 1.11 | uM | LJP5 | 1 | I21 | 72 | hr | 1476 | 1323 | 3694 | 0.3581 | -0.0693 |
| SK-BR-3 | Torin2 | 1.11 | uM | LJP5 | 2 | I21 | 72 | hr | 1476 | 1365 | 3694 | 0.3695 | -0.0504 |
| SK-BR-3 | Torin2 | 1.11 | uM | LJP5 | 3 | I21 | 72 | hr | 1476 | 1235 | 3694 | 0.3343 | -0.1090 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 1 | B15 | 72 | hr | 1476 | 1298 | 3694 | 0.3514 | -0.0806 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 2 | B15 | 72 | hr | 1476 | 1317 | 3694 | 0.3565 | -0.0720 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 1476 | 1295 | 3694 | 0.3506 | -0.0820 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 1 | P21 | 72 | hr | 1476 | 2582 | 3694 | 0.6990 | 0.4985 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 2 | P21 | 72 | hr | 1476 | 2713 | 3694 | 0.7344 | 0.5576 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 3 | P21 | 72 | hr | 1476 | 2726 | 3694 | 0.7379 | 0.5634 |